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ABSTRACT 
It is well established that the neurodegenerative process of Alzheimer's disease (AD) begins many 
years before symptom onset. This preclinical phase provides a crucial time-window for therapeutic 
intervention, though this requires biomarkers that could evaluate the efficacy of future disease-
modification treatments in asymptomatic individuals. The last decade has witnessed a proliferation 
of studies characterizing the temporal sequence of the earliest functional and structural brain 
imaging changes in AD. These efforts have focused on studying individuals who are highly 
vulnerable to develop AD, such as those with familial genetic mutations, susceptibility genes (i.e. 
apolipoprotein epsilon-4 allele), and/or a positive family history of AD. In this paper, we review the 
rapidly growing literature of functional imaging changes in cognitively intact individuals who are 
middle-aged: positron emission tomography (PET) studies of amyloid deposition, glucose 
metabolism, as well as arterial spin labeling (ASL), task-dependent, resting-state functional 
magnetic resonance imaging (fMRI) and magnetic resonance spectroscopy (MRS) studies.  The 
prevailing evidence points to early brain functional changes in the relative absence of cognitive 
impairment and structural atrophy, although there is marked variability in the directionality of the 
changes, which could, in turn, be related to antagonistic pleiotropy early in life. A common theme 
across studies relates to the spatial extent of these changes, most of which overlap with brain 
regions that are implicated in established AD. Notwithstanding several methodological caveats, 
functional imaging techniques could be preferentially sensitive to the earliest events of AD pathology 
prior to macroscopic grey matter loss and clinical manifestations of AD. We conclude that while 
these techniques have great potential to serve as biomarkers to identify at-risk individuals, more 
longitudinal studies with greater sample size and robust correction for multiple comparisons are still 
warranted to establish their utility.  
Search terms: Alzheimer's disease, neurodegeneration, preclinical dementia, functional, magnetic 
resonance imaging, positron emission tomography, neuroimaging, cognitive impairment. 
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INTRODUCTION 
There are now 46 million people living with dementia, and the number is expected to rise to 115 
million in 2050 (World Alzheimer Report 2015). Dementia is a relatively late feature in the 
pathophysiology of Alzheimer's disease (AD), with pathological changes beginning decades before 
symptom onset (Jack et al., 2013). Therefore, the identification of individuals prior to the onset of 
significant clinical symptoms is an important prerequisite for the initiation of earlier treatments, 
particularly as they are likely to have the greatest potential for delaying symptom onset and slowing 
down cognitive decline at the earliest disease stages.  
 
Biomarkers in clinical medicine are used to predict or detect specific illnesses, monitor disease 
progression, and predict response to treatment. The search for biomarkers to detect early 
neurodegenerative changes preclinically includes the exploration of structural neuroimaging (Mak 
et al., 2016a), functional neuroimaging (Wierenga & Bondi, 2007), genomics, proteomics, 
neurophysiology, cerebrospinal fluid (CSF), and blood analysis (Van Steenoven et al., 2016). Over 
the past decade, a variety of imaging techniques which probe brain function have been used to 
investigate early pathological changes in individuals at risk of developing AD. Research participants 
included those with a family history of AD, carriers of apolipoprotein epsilon-4 allele (ApoE4) and 
autosomal-dominant or familial AD (FAD) mutations in the genes of presenilin 1 (PSEN1), PSEN2 
and amyloid precursor protein (APP).  Given the close relationships between the presence of these 
risk factors and AD, studying these individuals provide an invaluable opportunity to chart the natural 
trajectory of disease progression in AD (Ritchie & Ritchie, 2012). 
 
As a two-part systematic review, we have recently surveyed the structural imaging changes in 
preclinical dementia (Mak et al., 2016a). As change in brain morphology is often a late event in the 
neurodegenerative cascade, changes detectable with functional imaging may precede grey matter 
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atrophy and white matter degeneration. The term functional MRI (fMRI) has become associated 
specifically with blood oxygen level dependent BOLD imaging; for the purposes of this review, 
however, we will consider a broader definition of functional imaging to include techniques which 
yield information on physiology and specific pathological processes as well as function. We will 
review the literature concerning functional imaging studies in middle-aged asymptomatic subjects 
under the age of 60 to survey subtle changes that arise years and even decades prior to the 
manifestations of cognitive decline. Findings will be drawn from (a) positron emission tomography 
(PET) studies of amyloid burden (11C-PIB or 18F compounds), cerebral glucose metabolism (b) 
perfusion MRI and task-based and resting-state functional magnetic resonance (fMRI) and (c) 
magnetic resonance spectroscopy (1H MRS). These techniques could have prognostic utility for 
identifying those at risk, predicting and monitoring disease progression and potentially the 
evaluation of a broad range of therapeutic interventions encompassing life-style changes, dietary 
improvements, and disease modifying therapies. 
 
METHOD 
The literature search used to obtain articles for the purpose of this review was done by searching 
Medline and PubMed, using key words, “preclinical” and “dementia” and “functional” and 
“neuroimaging” and “Florebetapir”, “Flumetamol”, “Florbetapen”, “Magnetic Resonance 
Spectroscopy”, “functional MRI”, “FDG-PET” and “PIB”. Other terms included “brain”, “imaging”, 
“resting-state”, “healthy”, “young” and “middle-aged”. Articles included were from the year 1990 till 
April 2016. We only considered human studies in English language. Articles had to describe the 
association between a known risk factor for dementia and neuroimaging changes or had to follow 
up a cohort originating in midlife or earlier with imaging undertaken at a later stage. Only studies 
involving functional neuroimaging modalities (PET and MRI) were included in this review. Relevant 
citations from the reference lists of identified articles were also reviewed.  
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POSITRON EMISSION TOMOGRAPHY 
Amyloid deposition 
The advent of PET amyloid ligands has enabled the in vivo investigation of fibrillar amyloid 
deposition, heralding a rapidly growing literature in both AD and its preclinical stages (see 
Rabinovici & Jagust, 2009 for a review). The first ligand with high specificity for amyloid was the 
11C-Pittsburgh Compound B (11C-PIB) (Klunk et al., 2004). Subsequently, three other 18F based 
amyloid ligands have been developed and licensed for clinical use (18F-florbetapir, 18F-florbetaben 
and 18F-flutemetamol) (O’Brien & Herholz, 2015). Several studies have reported strong agreement 
in uptake measures among the different PET amyloid ligands (Villemagne et al., 2012). 
 
In AD, the topography of amyloid follows a diffuse pattern with the prefrontal cortices, precuneus 
and posterior cingulate cortex being the earliest sites of vulnerability (Rabinovici & Jagust, 2009; 
Thal et al., 2002). In preclinical dementia, there is some evidence to suggest a distinct topographical 
pattern of amyloid (Figure 1A). In the first in vivo investigation of amyloid deposition in asymptomatic 
PSEN1 mutation carriers (~10 years before expected onset of cognitive symptoms), Klunk and 
colleagues reported preferential PIB binding to the striatal regions (Klunk et al., 2007). The in vivo 
findings were corroborated by histological evidence showing that the density of plaques in the 
striatum exceeded that of the cortex and subsequently confirmed by another study involving 7 
PSEN1 mutation carriers and 1 APP mutation carrier (Villemagne et al., 2009). These in vivo 
findings have prompted the hypothesis that the striatum is one of the earliest sites of amyloid 
deposition (Klunk et al., 2007), thereby challenging the notion that striatal plaques only occur at 
later histopathological stages (i.e. second phase of amyloid deposition) in AD (Braak & Braak, 1990; 
Thal et al., 2002). Others have reported increased amyloid burden in the adjacent thalamus and the 
cerebellum in asymptomatic FAD mutation carriers (Knight et al., 2011; Villemagne et al., 2009). 
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However, doubts remain over the universality of striatal amyloid across in FAD (Fleisher et al., 2012; 
Knight et al., 2011). The clinical relevance of PIB retention in FAD is still ambiguous. In Villemagne 
et al (2009), the patterns of PIB retention in both striatal and neocortical regions were not associated 
with disease severity or cognitive function. Neither were there significant differences in amyloid 
burden between dichotomized subgroups of Mini Mental State Examination (MMSE) scores (> 20 
or <= 20) and Clinical Dementia Rating (CDR) (>2 or <= 2). 
 
More recent studies from the Dominantly Inherited Alzheimer's Network study (DIAN) – a large-
scale investigation of MRI and PET data in FAD mutation carriers – have implicated the precuneus 
as an early site of amyloid burden, approximately up to 15 years before expected symptom onset 
(Bateman et al., 2012). These findings are in accordance with those from the Colombian Alzheimer’s 
Prevention Initiative Registry (API), which includes more than 1500 living members from the largest 
known autosomal-dominant AD kindred, 30% of whom are carriers of the PSEN1 E280A mutation 
(Lopera et al., 1997). A unique trait of the Columbian kindred is that it represents the most 
genetically and ethnically homogenous sample from the same geographical location. Fleisher and 
colleagues (2012) characterized the pattern of fibrillar amyloid deposition and estimated its temporal 
relation with clinical onset among 30 PSEN1 mutation carriers (20 – 56 years of age) and 20 
asymptomatic non-carriers. Using a voxel-wise approach, asymptomatic mutation carriers (n=19) 
demonstrated increased 18F florbetapir binding in widespread regions encompassing the 
precuneus, cingulate regions, temporoparietal regions, frontal grey matter and the basal ganglia 
(Fleisher et al., 2012). Notably, these findings remained significant after controlling for atrophy and 
partial volume adjustments. Consistent with data from the DIAN study (Bateman et al., 2012), the 
trajectory of amyloid deposition was estimated to follow a steep acceleration (16 and 21 years 
before mild cognitive impairment (MCI) and AD respectively) before slowing to a plateau before the 
estimated age of onset. 
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The Australian Imaging Biomarkers and Lifestyle (AIBL) study reported that 49% of ApoE4 carriers 
were found to be 11C-PIB positive in contrast to 21% among non-carriers (Rowe et al., 2010). In 
cognitively normal older subjects, the presence of ApoE4 has been associated with both increased 
and earlier amyloid deposition (Fleisher et al., 2013; Morris et al., 2010) as well as 3-fold increased 
odds of amyloid positivity (Mielke et al., 2012). Data from the Adult Children Study (ACS) cohort 
involving middle-older age individuals (stratified by family history for AD) have shown an age-related 
increase in mean cortical binding potential of PIB-PET that was associated with ApoE4 but not 
family history. Furthermore, the younger group (age < 55) did not show any significant associations 
between mean cortical binding potential (MCBP) with other CSF biomarkers and brain volumes 
(Xiong et al., 2011).  
 
Cerebral glucose metabolism  
The 18F 2-fluorodeoxy-D-glucose (FDG) PET tracer has been used to quantify aberrant cerebral 
metabolic rate of glucose in AD (Minoshima et al., 1997, 1995; see Schubert, 2005 for a review) In 
general, preclinical AD appears to be characterized by a hypometabolic profile in temporo-parietal 
cortices including the precuneus. In a study of 235 volunteers aged 50 – 65 years old with a positive 
family history of AD, 11 ApoE4 homozygotes were compared against 22 non-ApoE4 carriers. 
Despite being cognitively intact, the ApoE4 carriers had significantly decreased glucose metabolism 
in regions that are often affected in AD, including the posterior cingulate, temporo-parietal and 
prefrontal regions (Reiman et al., 1996). Of note, the posterior cingulate and precuneus were the 
most hypometabolic regions (Figure 1B), in line with AD studies where it is regarded as a site of 
confluence for various pathologies including amyloid deposition, cortical atrophy and 
hypometabolism (Buckner et al., 2005). These findings in middle-aged ApoE4 carriers were 
subsequently extended to a younger sample of ApoE4 heterozygotes well before midlife (n = 12; 
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20 – 39 years of age) (Reiman et al., 2004). Furthermore, the pathological relevance of these 
regional metabolic deficits was supported by a dose-dependent correlation between ApoE4 (none, 
one, or two copies) in the posterior cingulate cortex among middle-aged persons. The authors also 
demonstrated that the relationship was significantly stronger compared to that of hippocampal 
glucose metabolism or volume (Fisher’s R to Z test). These collective findings suggest that posterior 
cingulate hypometabolism appear to anticipate MTL atrophy and provide further evidence that 
functional imaging techniques might be more sensitive to subtle alterations in the early stages of 
the disease. 
 
In one of the few longitudinal studies, Reiman and colleagues investigated the progression of 
hypometabolism in 10 cognitively normal ApoE4 carriers (50 – 63 years of age) over 2 years. 
Compared to non-carriers, ApoE4 carriers showed significantly more severe metabolic deficits over 
time in the posterior cingulate, fronto-temporal cortices as well as basal forebrain and the thalamus 
(Reiman et al., 2001).  
 
Several studies have also demonstrated focal temporo-parietal metabolic deficits in FAD mutation 
carriers (Fleisher et al., 2015; Kennedy et al., 1995). Kennedy and colleagues showed an 
intermediate level of cerebral glucose metabolism in presymptomatic individuals between controls 
and symptomatic FAD carriers, whereas decreased metabolism in the precuneus was  found in 
presymptomatic PSEN1 carriers from the Columbian kindred (Fleisher et al., 2015). However, 
despite the consistent literature indicating hypometabolism in preclinical AD, the associations or 
differential contributions of FDG-PET and structural brain atrophy remains poorly understood. To 
address this question, Mosconi and colleagues conducted a multi-modal study of FDG-PET and 
MRI in a sample of 7 asymptomatic PSEN1 carriers (age: 35 – 49) (Mosconi et al., 2006). From a 
methodological perspective, this is one of the few studies in the literature that has corrected the 
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PET scans for partial volume effects (2 segment model of brain tissue and CSF). This is critical in 
FDG-PET studies because the extent of atrophy will artificially dilute of PET measurements, thus 
inflating the degree of hypometabolism in vulnerable regions and accentuating the group-
differences between carriers and non-carriers. Using the ROI approach to enable direct 
comparisons of atrophy and hypometabolism, the authors reported convincing evidence of 
hypometabolism in the MTL in the relative absence of atrophy. In addition, FDG-PET measurements 
were less variable than the MRI-based volume measurements, in turn resulting in stronger 
discriminatory sensitivity in the preclinical AD stage. Given that hypometabolism is thought to reflect 
synaptic dysfunction, these findings indicate that FDG-PET imaging could be more sensitive to such 
alterations that typically precede macroscopic grey matter atrophy.  
 
FUNCTIONAL MAGNETIC RESONANCE IMAGING  
Arterial spin labeling  
Arterial spin labeling (ASL) is a non-invasive MRI technique for the measurement of cerebral 
perfusion and it is emerging as another promising biomarker in the early stages of AD (see Hays et 
al., 2016 for a review). While cerebral glucose metabolism has been traditionally measured using 
radionuclide imaging as previously described (FDG-PET), its widespread utility has largely been 
mitigated by limited availability, radiation exposure and costs associated with nuclear imaging. In 
contrast, ASL provides a measure of cerebral blood flow (CBF) by using magnetically labeled 
arterial blood water as an endogenous tracer. Its increasing use has been supported by showing a 
high degree of agreement with FDG-PET (Musiek et al., 2012). Other advantages include (a) greater 
accessibility, (b) cheaper cost of MRI compared to PET, (c) safety benefits (i.e. free of exposure to 
ionizing radiation and intravenous contrast agent and (d) simultaneous acquisition within a structural 
MRI session (~ 6 – 10 minutes). 
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At present, there are relatively fewer ASL studies in preclinical AD, particularly in the young to 
middle-age groups. A previous study reported that resting CBF – particularly in the MTL –  was 
markedly increased (24%) in middle-aged individuals with ApoE4 and family history of AD. 
Interestingly, the at-risk group showed the opposite effect of reduced CBF in the MTL when 
challenged with an associative encoding task. The phenomena of increased baseline CBF was 
interpreted by the authors to represent a global compensatory mechanism to sustain activity in 
functionally impaired regions (Fleisher et al., 2009). These findings are in agreement with another 
study of individuals stratified according to maternal or paternal family history. Echoing previous 
findings where maternal history was associated with a more severe neurodegenerative profile 
(Okonkwo et al., 2012), the authors found that individuals with a maternal history of AD showed 
greater hypoperfusion in the hippocampal and fronto-parietal regions compared to both controls as 
well as individuals with a paternal family history of AD. The significance of these group differences 
also persisted after voxel-wise correction for grey matter atrophy. These findings are also consistent 
with a previously described FDG-PET study (Mosconi et al., 2009), and together add to a growing 
body of evidence implicating maternal family history of AD in greater cognitive decline (Debette et 
al., 2009).  
 
Others have demonstrated differential impact of ApoE4 on resting CBF across the lifespan 
(Wierenga et al., 2013). While older ApoE4 (age = 75) adults showed decreased CBF in widespread 
regions, younger ApoE4 (age = 24) had increased perfusion particularly in the anterior cingulate 
cortex, which was, in turn, correlated with executive function (Figure 1C). However, other studies 
have not found any difference between young ApoE4 carriers (age = 28) and non-carriers (age = 
29) (Filippini et al., 2009). These inconsistencies could be attributed to the different methodological 
approaches. In contrast to the whole brain voxel-wise approach (Wierenga et al., 2013), an ROI-
based analysis was used in Filippini et al to restrict CBF comparisons to the hippocampus, midbrain 
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and cerebellum. As such, any focal or subtle ApoE4 signal at the voxel-level may have been masked 
out by the averaging of voxels across the ROIs. 
 
Task-based fMRI 
fMRI offers considerable promise as a non-invasive technique that is sensitive to early functional 
changes in asymptomatic individuals. It provides an indirect measure of neuronal activity through 
the inference of changes in blood oxygen level dependent (BOLD) fMRI signal (Logothetis, 2008). 
Task-based fMRI studies typically compare BOLD signals that are evoked during one condition (i.e. 
remembering a word stimuli) to BOLD signals associated with a baseline condition or control task.  
 
ApoE4 carriers have shown reduced hippocampal and MTL activations during task performance 
involving episodic encoding, visual naming and letter fluency (Nichols et al., 2012; Smith et al., 
1999; Trivedi et al., 2006). However, decreases in functional activation have not been universally 
reported in ApoE4 carriers (Dennis et al., 2010; Filippini et al., 2009; Quiroz et al., 2010). For 
instance, hippocampal hyperactivity has been evoked during encoding in younger ApoE4 carriers 
(age = 28), independent of grey matter atrophy and perfusion changes (Figure 1D). These findings 
are in parallel with those of Dennis et al (2010), where young ApoE4 carriers (age = 23.2) also 
exhibited MTL hyperactivation during encoding despite comparable memory performance and grey 
matter volumes relative to non-carriers (Dennis et al., 2010). These reports, taken together with 
previous ASL studies in younger ApoE4 carriers, add further support to the notion that the role of 
ApoE4 is not uniform across the life-span. Based on the young age of the sample and the lack of 
behavioral differences between groups, MTL hyperactivity in ApoE4 carriers could be interpreted 
as inefficient processing associated with dysfunction in the medial temporal lobe or compensatory 
processing necessary to achieve similar cognitive output to that in non-carriers (Dennis et al., 2010). 
Interestingly, the interactions between ApoE4 allele and functional changes in young adults may 
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also be modulated by the difficulty of the task in question (Chen et al., 2013). Notwithsanding the 
caveats of a small sample size (n = 9 in each group) and lenient statistical thresholding (p < 0.01 
uncorrected), Chen and colleagues showed that low-load working memory tasks (N-Back) evoked 
hyperactivation in ApoE4 carriers, although this effect was diminished with increasing working 
memory load. In contrast, non-carriers continued to show increasing levels of functional activity 
during the moderate and higher working memory levels of the task. 
 
Task-based functional changes have also been investigated in FAD mutation carriers (Braskie et 
al., 2013; Mondadori et al., 2006; Quiroz et al., 2010; Ringman et al., 2011). In a previous study of 
an FAD family (n = 5, estimated age of clinical manifesation = 48 years), a young PSEN1 mutation 
carrer (age = 20) also showed hyperactivation in memory-related networks during episodic learning 
and retrieval tasks compared to controls (Mondadori et al., 2006). Conversely, weaker activations 
were observed in the middle-aged mutation carrier, who has an amnestic MCI profile (age = 45). 
Although these findings were not corrected for atrophy, the authors noted that manually-segmented 
MTL volumes were comparable between the FAD family members and the controls. These findings, 
albeit restricted to 2 PSEN1 carriers, were later supported by a larger study of the Columbian 
kindred (n = 20 carriers, age = 33) (Quiroz et al., 2010). Despite exhibiting similar cognitive profiles 
and preserved hippocampal volumes compared to controls, the young PSEN1 carriers showed 
hippocampal hyperactivation during encoding tasks of novel associations. These findings are in 
agreement with observations of decreased parietal inhibition during a memory encoding task in the 
youngest group of PSEN1 carriers studied to date (n = 19, age = 14) (Quiroz et al., 2015). Overall, 
the findings of hyperactivation – indicative of functional dysregulation – in young at-risk individuals 
bear resemblance to previous reports in MCI and AD (Dickerson et al., 2005), and collectively fit 
with the model that postulates a transient phase of functional hyperactivation followed by a steep 
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decrease in functional activation as neuronal populations gradually lose their ability to engage in 
compensatory mechanisms  (Dickerson et al., 2005). 
 
Resting-state fMRI studies 
Resting-state fMRI (RS-fMRI) is a relatively recent technique to investigate spontaneous low-
frequency fluctuations in BOLD signals. In rsfMRI studies, subjects are asked to rest with their eyes 
closed or fixated on a cross-hair. The spontaneous temporal correlations are thought to be 
manifestations of intrinsic functional connectivity across brain networks (RSNs) (Biswal et al .,1995), 
which could be interrogated with seed-based or data-driven independent component analyses 
(Beckmann, 2005). 
 
The effects of ApoE4 on brain networks have been increasingly studied in preclinical AD, revealing 
functional alterations in overlapping brain regions that are disrupted in AD (Sheline & Raichle, 2013). 
Of particular interest is the default mode network (DMN), which was first described by Raichle and 
colleagues using PET data (Gusnard & Raichle, 2001; Raichle et al., 2001). The DMN encompasses 
the midline, frontal, MTL and parietal regions as well as the posterior cingulate cortex (Buckner et 
al., 2005). A growing body of evidence has implicated the DMN across the spectrum from normal 
aging to MCI and AD (Buckner et al., 2005; Lustig et al., 2003). The relevance of the DMN in the 
pathophysiology of dementia is also supported by the observations that its constituent regions are 
often the sites of early and focal atrophy, reduced perfusion/metabolism as well as fibrillary amyloid 
deposition (Buckner et al., 2005; Jack et al., 2013; Klunk et al., 2004). Therefore, the failure to 
suppress the DMN during task engagement may prove to be a promising biomarker for earlier 
identification of AD pathology. 
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Abnormal DMN connectivity has been described among ApoE4 (Fleisher et al., 2009; Goveas et 
al., 2013; Patel et al., 2013) and FAD mutations carriers (Chhatwal et al., 2013). A previous study 
of presymptomatic ApoE4 carriers also reported decreased DMN connectivity in the absence of 
amyloid burden (Sheline et al., 2010) (Figure 1D). Indeed, a key strength of this study was the use 
of in vivo amyloid PET imaging to (a) identify PIB-positive or negative individuals before (b) sub-
stratification into those with and without an ApoE4 allele, thereby allowing the authors to determine 
whether the functional effects of ApoE4 is independent of the cardinal initiating event in AD (Bloom, 
2014). 
 
Consistent with earlier suggestions of an antagonistic pleiotropic effect of the ApoE4 allele 
(Wierenga et al., 2013), younger ApoE4 carriers have shown hippocampal hyperconnectivity within 
the DMN in the absence of cognitive deficits, structural atrophy and hypoperfusion (age range: 20 
– 35 years) (Filippini et al., 2015). Another study has investigated a potential gender-ApoE4 
interaction, revealing decreased functional connectivity between the hippocampus and the DMN in 
female carriers (Heise et al., 2014). There is also emerging evidence that resting-state analyses 
may be more sensitive than task-based fMRI to early perturbations in preclinical AD, as evidenced 
by a larger effect size (3.35 vs 1.39) in distinguishing asymptomatic at-risk individuals (ApoE4 and 
positive family history) from controls (Fleisher et al., 2009). There are several advantages of resting-
state fMRI: (a) independence from task performance, which could be influenced by multiple factors 
unrelated to the underlying disease (i.e. interpretation of task demands, motivation and cognitive 
fluctuations); (b) ease of standardization across multi-site studies, (c) data collection from patients 
with substantial cognitive impairment (i.e. avoidance of floor effects); (d) ability to investigate 
multiple RSNs from the same datasets as opposed to unique experimental paradigms that are 
catered to specific cognitive domains. 
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MAGNETIC RESONANCE SPECTROSCOPY 
In vivo 1H MRS allows non-invasive biochemical quantification in defined regions of the brain, and 
characteristic metabolite changes have been  recognized  in  AD and other dementias since the 
early 1990’s (Graff-Radford et al., 2014). Multiple metabolites, each thought to reflect different 
cellular and molecular aspects of the neurodegenerative process, can be measured during a single 
acquisition: (a) N-acetylaspartate (NAA) is a marker of neuronal integrity; (b) myoinositol (mI) levels 
are thought to predominantly reflect glial activation; (c) Choline containing compounds (Cho) are 
associated with membrane turnover and inflammatory processes; and metabolite levels are 
frequently expressed as ratios to creatine/phosphocreatine (Cr) . Although a substantial literature 
exists in dementia and MCI, there are currently relatively few studies in the asymptomatic stages of 
AD. In the Columbian kindred described previously, variations of 1H MRS measurements in the 
posterior cingulate and precuneus have been shown to separate asymptomatic PSEN1 mutation 
carriers from non-carriers with high accuracy (Londono et al., 2014). Another study demonstrated 
decreases in the posterior cingulate NAA/Cr and NAA/mI among presymptomatic PSEN1/APP 
mutation carriers (n = 7). In addition, the magnitude of these deficits were correlated with the 
proximity of expected age of onset (Godbolt et al., 2006). Despite the scarcity of 1H-MRS studies in 
FAD mutation carriers, there is convergent evidence that lower NAA/Cr in the posterior cingulate 
increases the risk of dementia in MCI (Kantarci et al., 2009). Taken together, these studies provide 
important evidence that metabolic changes, particularly within the posterior cingulate and 
precuneus (Figure 1E), can be detected in presymptomatic mutation carriers before the emergence 
of cognitive impairment. 
 
CAVEATS AND METHODOLOGICAL CONSIDERATIONS 
Studying younger subjects at risk of familial AD has the advantage of eliminating or reducing the 
effects of other age-related comorbidities (e.g. hypertension) that may play a confounding role in 
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cerebral pathology (e.g. ischemic changes). However, there are limitations to the degrees in which 
the findings in FAD are both (a) consistent and (b) generalizable to sporadic late onset AD, which 
could in turn hamper efforts to detect treatment effects due to a suboptimal choice of biomarker. 
There is also a scarcity of longitudinal functional studies, precluding definitive conclusions about the 
ability of the functional imaging techniques to track disease progression. To date, most cross-
sectional studies in FAD mutation carriers have calculated the “estimated age of onset” (EOY) in 
presymptomatic carriers, but it is essentially just a construct to determine biomarker changes as a 
function of an individual’s position along the trajectory of disease course. The validity of EOY is 
inherently limited by many factors including the assumption that the parental age of onset is an 
accurate approximation for the offspring carriers. Future prospective longitudinal studies are thus 
required to follow asymptomatic FAD carriers to the symptomatic stages to confirm the predictive 
validity of functional changes. In anticipation of future longitudinal studies, the present FAD findings 
could ideally be compared against cohorts of cognitively-normal at-risk individuals, such as those 
from the Alzheimer's Disease Neuroimaging Initiative (ADNI), Australian Imaging Biomarkers and 
Lifestyle (AIBL), WRAP (7 – 10 years of multimodal imaging data). The PREVENT study (Ritchie & 
Ritchie, 2012), which is an on-going study from our group, is also collecting large amounts of 
imaging data (including MRI, DTI, MRS and fMRI) from people aged 40 to 59 at baseline, as well 
as detailed neuropsychological assessment using the COGNITIO test battery (Ritchie et al., 2014) 
designed for pre-clinical cognitive assessment as well as genetic analyses.  
 
In our review, most studies have not performed partial volume correction, opting instead to (a) 
include grey matter volume as a covariate and/or (b) establish the relative absence of grey matter 
atrophy.  While these statistical adjustments are improvements over the lack of PVC, grey matter 
volumes are usually collinear with other covariates of interest such as age. It is imperative that future 
functional studies account for grey matter atrophy which could exacerbate the spillover 
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contamination of PET/fMRI data. Due to the poor spatial resolution of PET and fMRI data, the 
intensity of a given voxel will be an aggregate of the local uptake/activity within the region of interest 
(i.e. hippocampus) and voxels from other tissue classes (i.e. white matter or surrounding CSF). This 
issue may be more problematic in cortical analyses because the cortical ribbon has a thickness 
(generally 2 to 3 mm) that is similar to the typical voxel diameters in PET and fMRI data. Since the 
partial volume effect (PVE) is proportionate to the amount of atrophy, group differences may be 
artificially attenuated (amyloid measurements) or inflated (FDG-PET, ASL and fMRI) if atrophy is 
not accounted for. 
 
CONCLUSIONS 
The selective investigation of individuals with increased risks of AD presents an invaluable 
opportunity to elucidate the presence, magnitude and spatial mapping of functional imaging markers 
associated with the insidious development of dementia from the presymptomatic state. The 
evidence reviewed herein strongly suggests that changes as seen on functional imaging are early 
features of AD. In line with the “amyloid cascade” hypothesis, PET studies have established the 
presence of amyloid accumulation in FAD and ApoE4 carriers as early as 15 years before ensuing 
cognitive decline. However, there are still unresolved questions concerning the specificity and the 
clinical implications of regional amyloid pathology (i.e. striatal regions) as there is insufficient 
evidence for a close relationship with cognitive impairment. Metabolite abnormalities detected by 
MRS have also been demonstrated many years before predicted onset of dementia in FAD. 
Downstream events of the neurodegenerative cascade, such as hypometabolism and decreased 
CBF, are temporally closer to cognitive decline and may serve as better markers of disease 
progression. FDG-PET and ASL studies have revealed hypo-metabolism and perfusion within 
characteristic AD regions, and that these changes may even precede structural atrophy. Other 
research groups have devised novel experimental paradigms that are designed to challenge 
 18 
specific cognitive domains. Although there is clear evidence for physiological disruptions in 
preclinical AD, the directionality and interpretation of task-evoked fMRI changes are still being 
contested. That could be also age-dependent nuances in the associations between AD risk factors 
and functional imaging parameters. For instance, the MTL is associated with an upsurge of 
functional activity in younger ApoE4 carriers before demonstrating hypoactivation in older carriers 
as in patients with MCI and AD. Finally, although our previous review in preclinical AD has identified 
vulnerable foci of structural degeneration (Mak et al., 2016b), the independence and antecedence 
of functional deficits relative to grey matter atrophy suggests that these techniques may well be 
more sensitive to disease-related changes in preclinical AD. With more validation efforts in larger 
samples and longitudinal studies, we anticipate that functional modalities are well-poised to serve 
as outcome measures in future clinical trials. 
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FIGURE AND TABLES 
 
Figure 1. Schematic figure of the principal imaging findings. (A) At-risk individuals exhibit an atypical pattern of amyloid accumulation 
within the striatal regions, thalamus and the cerebellum. Increased amyloid has also been reported in the precuneus and the posterior 
cingulate cortex, both of which are early sites of vulnerability in MCI and AD; (B) The MTL is frequently charcterized by 
hypometabolism, whereas others have reported stronger associations between ApoE4 and hypometabolism within the posterior 
cingulate and precuneus compared to MTL volumes or metabolism; (C) Individuals with ApoE4 and a family history of AD showed 
decreased perfusion in the MTL that is independent of grey matter atrophy. There is also evidence to imply compensatory hyperfusion 
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in the anterior cingulate cortex among younger ApoE4 carriers; (D) fMRI task-based studies have consistently demonstrated 
hypoactivation of the MTL during episodic memory tasks in older ApoE4 subjects (down-ward arrow). However, younger at-risk 
individuals tend to show hyperactivation (upward arrow). The DMN is frequently associated with functional abnormalities in ApoE4 
and FAD mutation carriers. The effect size of rsfMRI differences has been reportedly greater compared to task-based fMRI; (E) 1H-
MRS studies in FAD mutation carriers have reported variations of brain metabolite levels in the posterior cingulate cortex and 
precuneus. Abbreviations: MCI = Mild cognitive impairment; AD = Alzheimer’s disease, FAD = familial Alzheimer’s disease; ApoE4 = 
apolipoprotein epsilon-4 allele; MTL = medial temporal lobe, RS-fMRI = resting-state functional magnetic resonance imaging; DMN 
= default mode network; 1H-MRS = magnetic resonance spectroscopy. 
 
